Regenerative Patch Technologies Provides Update on Phase 1/2a Clinical Trial of Stem Cell-Engineered Implant for the Treatment of Dry Age-Related Macular Degeneration prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share:
ISELIN, N.J., May 12, 2021 (GLOBE NEWSWIRE) Outlook Therapeutics, Inc. (NASDAQ:OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will host a Virtual Clinical Day for analysts and accredited institutional investors with live video webcast (details below) on Thursday, May 20, 2021 from 11:00 AM – 1:00 PM ET.
During the Virtual Clinical Day, Outlook Therapeutics will provide an overview of its lead program, ONS-5010 / LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), its ongoing Phase 3 study in wet AMD, NORSE TWO, and its plans for a potential commercial rollout.
E-Mail
IMAGE: Researchers developed an experimentally validated advanced computer model that reproduces the shapes and positions of millions of nerve cells in the eye, as well as the physical and networking properties. view more
Credit: Gianluca Lazzi
There are millions of people who face the loss of their eyesight from degenerative eye diseases. The genetic disorder retinitis pigmentosa alone affects 1 in 4,000 people worldwide.
Today, there is technology available to offer partial eyesight to people with that syndrome. The Argus II, the world s first retinal prosthesis, reproduces some functions of a part of the eye essential to vision, to allow users to perceive movement and shapes.
Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.